So you make a good point @thenewinvest0r, especially on the heels of finally stating what they are modelling for costs.
He said they thought costs for P3 completion would be US$50 - $60m, the presentation showed 400 n (which many have pointed out), so the math works out to be circa US$150,000 per patient, that is a rather staggering number.
We were always guessing how much they previously spent and how much the extra screening (retinal etc) was costing.
I sure hope that 400 n for the next part of P3 is correct, otherwise that $150,000 per head is going to blowout total costs very quickly.
Sharewise Presentation 22/7/24, page-81
-
- There are more pages in this discussion • 59 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78837 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 36290 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |